title: Erythropoietin attenuates motor impairments induced by bilateral renal ischemia/reperfusion in rats.
abstract: Neurologic sequelae remain a common and destructive problem in patients with acute kidney injury. The objective of this study was to evaluate the possible neuroprotective effect of erythropoietin (EPO) on motor impairments following bilateral renal ischemia (BRI) in two time points after reperfusion: short term (24 h) and long term (1 week). Male Wistar rats underwent BRI or sham surgery. EPO or saline administration was performed 30 min before surgery (1000 U/kg, i.p.). Explorative behaviors and motor function of the rats were evaluated by open field, rotarod, and wire grip tests. Plasma concentrations of blood urea nitrogen (BUN) and creatinine (Cr) were significantly enhanced in BRI rats 24 h after reperfusion. BRI group had only an increased level of BUN but not Cr 1 week after reperfusion. Impairment of balance function by BRI was not reversed by EPO 24 h after reperfusion, but counteracted 7 days after renal ischemia. Muscle strength had no significant differences between the groups. BRI group had a decrease in locomotor activity, and EPO could not reverse this reduction in both time points of the experiment. Although EPO could not be offered as a potential neuroprotective agent in the treatment of motor dysfunctions induced by BRI, it could be effective against balance dysfunction 1 week after renal ischemia.
authors.affiliation: Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Mahshid
authors.initials: M
authors.lastname: Tahamtan
authors.affiliation: Department of Physiology, The Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Seyed M S
authors.initials: SM
authors.lastname: Moosavi
authors.affiliation: Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Vahid
authors.initials: V
authors.lastname: Sheibani
authors.affiliation: Pouyesh Darou Product Company, Tehran, Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Nayebpour
authors.affiliation: Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.|Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
authors.forename: Saeed
authors.initials: S
authors.lastname: Esmaeili-Mahani
authors.affiliation: Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Shabani
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications; D000818:Animals; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000378:metabolism; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000494:pharmacology*; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D000068079:Motor Disorders / Q000188:drug therapy* / Q000209:etiology*; D053580:Muscle Strength / Q000187:drug effects*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015424:Reperfusion / Q000379:methods; D015427:Reperfusion Injury / Q000150:complications*
chemical_list: D018696:Neuroprotective Agents; D004921:Erythropoietin; D003404:Creatinine
keywords: erythropoietin; motor impairments; neuroprotective; renal ischemia